A apoptotic and proliferative activity of mouse gastric mucosa following oral administration of fumonisin B1

Ali Mohammad Alizadeh 1, 2*, Fahimeh Mohammadghasemi 3, Kazem Zendehe del 1, Zahra Kamyabi-moghaddam 4, Abbas Tavassoli 4, Fatemeh Amini-najafi 4, Alireza Khosravi 5

1 Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran
2 Cancer Model Research Center, Tehran University of Medical Sciences, Tehran, Iran
3 Cellular and Molecular Research Center, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran
4 Department of Pathology, Faculty of Veterinary Medicine, Tehran University, Tehran, Iran
5 Medical Parasitology and Mycology Department, School of Medicine, Tehran University, Tehran, Iran

ARTICLE INFO

Objective(s): Fumonisins are a group of toxic and carcinogenic mycotoxins, which contaminate the grains and their products. The aim of this study was to examine the apoptotic and proliferative activity of mouse gastric mucosa following administration of fumonisin B1 (FB1).

Materials and Methods: Twenty-nine female mice divided into treatment (n=15) and control (n=14) groups. The treatment group received FB1 (150 mg/kg diet) for 16 weeks. The gastric atrophy was allocated using grading criteria modeled on the updated Sydney System. Immunohistochemistry studies were performed for evaluation of apoptosis and proliferative activity in gastric mucosa.

Results: Mild to moderate gastric atrophy were observed in microscopic findings of the gastric mucosa in treated animals (P<0.05). Number of parietal cells significantly decreased in the treatment group in comparison with the control (P<0.05). Treatment with FB1 for 16 weeks significantly reduced both gastric mucosa height and mitotic index in the gastric glands (P<0.05). TUNEL- and Bax-labeled positive cell numbers significa ntly increased in the FB1-treated group compared to the control (P<0.05). In addition, proliferative activity of gastric glands in the treated group was significantly lower than the control (P<0.05).

Conclusion: Oral administration of FB1 caused atrophy in gastric mucosa both via increasing of apoptosis and suppressing the mitotic activity of these cells.

Introduction

Fumonisin which belongs to the mycotoxins family was initially derived from the culture medium of Fusarium verticillioides in South Africa in 1988 (1). Fumonisin B1 (FB1), B2 and B3 are the most abundant types of fumonisins among which the B1 type can be found in maize, rice, sorghum, wheat and soybean (2). Fumonisins are absorbed through digestive system and affect organs at cellular level (3). The biological effects of fumonisins have been studied in the past 20 years and have shown their toxic and carcinogenic side effects (4, 5). The mechanism(s) of fumonisin toxicity is complex. Their most important role is contribution to sphingolipid synthesis, sphinganine and sphingosine aggregation and thus causing defective membrane duties (3). They have also other cellular effects such as cellular growth regulation, differentiation, apoptosis and cell morphology changes (3, 6). On the other hand, repeated accumulation of free cellular sphingoid bases acts as cancer promoter and mutative factor (3). A correlation between fumonisin contaminated maize (>100 mg/kg diet) and the esophageal cancer has been found (7). In vitro, fumonisins (1 to 10 μg) may activate apoptosis, inhibit proliferation and increase inflammatory cytokine production (8, 9). In vivo studies have also shown that fumonisins can cause intestinal villi atrophy and absorption disorder (10). Administration of FB1 in a dose of 8 to 10 mg/kg in pig's diet, changes cytokine profiles and reduces special antibody responses (10, 11). In addition, long-term consumption of fumonisin may also change intestinal cell morphology such as goblet cell reduction, cause atrophy and decrease mucin secretion (12).

Previous studies have shown a strong correlation between gastric atrophy, and incidence of the gastric and esophageal cancers (13-16). Epidemiologic studies in some areas of South Africa, Japan, China and Iran have shown the high incidence of the esophageal cancer with the FB1 contaminated maize high consumption compared to low risk regions of esophageal cancer that had a lower intake of the FB1 contaminated maize (13, 17-20). Previous
ecological studies similarly suggested positive correlation between fumonisin contamination of cereals and the risk of cancers (17, 21). Some epidemiological studies have also shown a correlation between consumption of FB1 contaminated foods and the risk of esophageal cancer (7, 18). Due to high incidence of esophageal cancer in developing countries including Iran, and the existence of toxic fumonisin in their grains (20), this hypothesis supports that fumonisin can act as a carcinogenic factor in high incidence rate of gastric and esophageal cancer in developing countries. Thus, the objective of the present study is to detect apoptotic and proliferative activity of mouse gastric mucosa following administration of FB1 through histopathological and immunohistochemical methods.

Materials and Methods

Food preparation

Fumonisin B1 (a gift by prof Khosravi AR from Tehran University, Iran) was mixed with rat chow purchased from Pars Animal Feed Co Iran. First, the animal food was completely ground (SK 100 comfort Gubelisen, Retsch, Germany). FB1 was mixed with ground pellet for 30 min and then tap water was added to the mixture. The prepared dough was then shaped into strips and remade into pellet in a special pellet-making device. The pellets were finally put for 24 to 72 hr into an oven set at 75°C to make it dry and ready to use.

Animals

Female mice (25 to 30 g) were maintained in animal quarters under standardized conditions with a 12 hr light/dark cycle, 20 to 22°C ambient temperature and 40 to 50% humidity with free access to rat chow and water. All experimental procedures were performed according to the guidelines of the Animal and Human Ethical Committee of Tehran University of Medical Sciences.

The study design

Twenty-nine female mice divided into the treatment (N=15) and control (N=14) groups. Animals in the treatment group received FB1 (150 mg/kg diet) for 16 weeks (22). Mice were weekly weighed and euthanized at the end of 16th weeks. They were dissected and their stomachs were removed. In all animals, the body of stomach was sampled, fixed in 10% formaldehyde, passedaged and embedded in paraffin. Apoptotic changes were evaluated by immunohistochemistry using terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL), Bcl-2 and Bax staining. For evaluation of proliferative activity of gastric mucosa Ki-67 staining were used.

Histopathological study

Gastric atrophy was allocated using grading criteria modeled on the updated Sydney System (23, 24) as follows: (0) No parietal cell loss; (I) Mild parietal cell loss, up to 25%; (II) Moderate parietal cell loss, 25 to 75% and (III) Severe parietal cell loss, more than 75%. Gastric glandular and mucosal heights were also measured using graticule linear method as previously described (25).

Immunohistochemical assay

Briefly, the sections were treated with 3% (v/v) H2O2 at room temperature, blocked with 10% (v/v) goat or rabbit serum (Nichirei, Tokyo, Japan), and incubated with a rabbit monoclonal antibody against Ki-67 (Thermo Fisher Scientific Inc., San Jose, CA) diluted 1:200. Then, the sections were incubated with biotinylated goat anti-rabbit IgG (Nichirei). The sections were incubated with a solution of streptavidin-conjugated horseradish peroxidase (Nichirei) according to the manufacturer's recommendations. The sections were counterstained with hematoxylin before dehydration and mounting (26). In each animal, mitotic indexes were measured in 10 to 15 gastric glands in transverse sections. At first, the Ki-67 positive cells were counted and divided into Ki-67 positive and non-positive cells. The obtained figure was then multiplied by 100 and reported.

In situ nick end-labeling assay

In situ detection of cells with DNA strand breaks was performed in formalin-fixed, paraffin-embedded tissue sections by TUNEL according to the manufacturer's instructions (Roche, Germany). Paraffin sections of 5 μm thick were deparaffinized, and endogenous peroxidase was blocked by immersing the sections in phosphate-buffered saline (PBS) containing 0.5% H2O2 for 15 min. For proteins nuclei stripping, tissue sections were incubated with proteinase K (Roche, Germany) (20 μg/ml) for 10 min. The sections were incubated with a mixture of terminal deoxynucleotidyl transferase (TdT) and reaction buffer containing digoxigenin-labeled dUTP. Hematoxylin staining was performed followed by incubation with anti-digoxigenin antibody conjugated with peroxidase. Positive cells containing the fragmented nuclear chromatin which is a characteristic of apoptosis have brown-stained nuclei. In each animal, 2 to 3 slides and in each slide, 5 microscopic fields were studied. TUNEL-positive cell number in each field was divided by apoptotic + non apoptotic cells and expressed as percentage (27).

Bcl-2 and bax detection

Immunohistochemistry was carried out on 5 μm tissue sections from formalin-fixed paraffin blocks using the avidin-biotin immunoperoxidase method. Sections were stained by monoclonal mouse/Rabbit Bcl-2, Bax oncoprotein (DAKO Corporation, USA) using a K0673 LSAB2 detection system (DAKO Corporation, USA) according to the manufacturer's
instructions. Briefly, the paraffin sections were deparaffinized with xylene and rehydrated through a series of descending graded ethanol solutions. Endogenous peroxidase activity was blocked by incubation for 15 min in 0.3% H₂O₂ buffer. To unmask the epitopes of Bcl-2 and Bax, a microwave processing pretreatment was carried out in a citrate buffer, pH = 6.0 for 10 min. A biotinylated secondary antibody and an avidin-biotin complex with horseradish peroxidase were applied, followed by addition of the chromogen. Finally, slides were counterstained with hematoxylin and observed with a light microscope. In each animal, 2 to 3 slides and in each slide, 5 microscopic fields were studied. Bcl-2 and Bax positive cell number in each field were divided by apoptotic+non apoptotic cells and expressed as percentage (28).

**Statistics**

Student’s t-test was used to find the differences between TUNEL, Bax-and-Bcl-2 labeled positive cell number and atrophy. Data were expressed as mean ± SEM. P<0.05 considered statistically significant. Statistical analysis was performed using SPSS statistical software version 16.

**Results**

**General observations**

Out of 30 mice, one died due to unknown reason three weeks after starting nutrition in control group. Both in treated and control groups, the weight has been increased but not significantly. Body weight rose steadily to reach a plateau after about 8 weeks in all mice, but showed a slight fall in the treated group in the last few weeks. There were no significantly differences in food intake (g/day) in the control and treatment groups. Fumonisin B1 fed animals demonstrated no evidence of weight loss, and no gross organ changes were observed at necropsy. No behavioral changes were observed in the mice during the course of administration, or in the ensuing follow-up period.

**Histopathological parameters observations**

Microscopic findings of the gastric mucosa in the treated animals revealed a mild to moderate gastric tissue atrophy (P<0.05). Parietal cells significantly decreased in the treatment group (12±0.3) compared with the control (24±1.3) (P<0.05) (Figures 1 and 2). In addition, treatment with FB1 for 16 weeks, significantly reduced both gastric mucosa height (345.00±68.04 μ vs. 512.85±86.93 μ) and mitotic index in gastric glands (43.22±16.67 % vs. 72.67±10.50 %) (P<0.05) (Table 1). In both groups, the mitotic cells observing in basal part of gastric glands, indicated stem cells activity (Figure 2).

Scatter TUNEL positive cells were observed in controls among the gastric glands (Figure 3). The percentage of TUNEL-positive cells in FB1 treated group were 1.56±0.21 vs. 0.56±0.11, and it was significantly higher than controls (Table 1).

In control animals, the Bcl-2 positive cells were mostly observed in surface and neck mucosal cells of the gastric glands. Immunoactivity with Bcl-2 in control group was 8.90±0.33, which was higher (P<0.05) than the same cells in treated group (Figure 4 and Table 1). However, Bax immunoactivity in gastric mucosa was statistically higher in the FB1 group than the control (P<0.05) (Figure 5). Treatment with FB1 caused a decrease in Bcl-2/Bax ratio compared to the control group (P<0.05) (Table 1).

**Discussion**

In this study, FB1 significantly reduced parietal cell number together with gastric body glandular cell height and caused pronounced atrophy. This study showed that administration of fumonisins B1 for 16 consecutive weeks in mouse induces atrophy in

![Figure 1. Light photomicrograph of mice gastric gland (A) in control group, normal parietal cells present in the mucosa and (B) in treatment group; a few parietal cells present in the final microscopy (H & E, 400×)](Image 57x659 to 283x769)

**Figure 2. Light photomicrograph from mice gastric mucosa. Brown cells indicate Ki-67 positive cells. Note to reduce mitotic index and height in gastric mucosa (Gm) in fumonisin treated animal (B & b) in compared to control (A & a). Bar: 50 μ.**

![Figure 2. Light photomicrograph from mice gastric mucosa. Brown cells indicate Ki-67 positive cells. Note to reduce mitotic index and height in gastric mucosa (Gm) in fumonisin treated animal (B & b) in compared to control (A & a). Bar: 50 μ.](Image 304x659 to 530x769)

### Table 1. Effects of fumonisins B1 on apoptosis and proliferative activity of cells in mouse gastric mucosa

<table>
<thead>
<tr>
<th>Groups</th>
<th>N</th>
<th>Apoptotic index (%)</th>
<th>Bcl-2 (%)</th>
<th>Bax (%)</th>
<th>Bcl-2/Bax</th>
<th>Gastric mucosa height (μ)</th>
<th>Gastric glands mitotic index (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>14</td>
<td>0.56±0.11</td>
<td>8.90±0.33</td>
<td>1.74±0.91</td>
<td>6.33±4.00</td>
<td>513±97</td>
<td>7.3±11</td>
</tr>
<tr>
<td>FB1</td>
<td>15</td>
<td>1.56±0.21</td>
<td>16.21±1.01</td>
<td>0.08±0.01</td>
<td>345±68</td>
<td>43±17</td>
<td></td>
</tr>
</tbody>
</table>

Data are presented as mean ± SEM. *P<0.05 vs. control group. FB1: fumonisins B1
Atrophy of gastric epithelium by fumonisin B1

Figure 3. Light photomicrograph from mice gastric mucosa. Arrows show brown nuclear’s cells indicating TUNEL positive cells. Control (A & a), Treated animals (B & b). Bar: 50 µ. Magnifications in A & B: 200 × and in a & b: 400 ×

Figure 4. Light photomicrograph from mice gastric mucosa. The quadrate shows brown cells indicating Bcl-2 positive cells. Control (A & a), Treated animals (B & b). Bar: 50 µ. Magnifications in A & B: 200 × and in a & b: 400 ×

Figure 5. Light photomicrograph from mice gastric mucosa. The quadrate shows brown cells indicating Bax positive cells. Control (A & a), Treated animals (B & b). Bar: 50 µ. Magnifications in A & B: 200 × and in a & b: 400 ×

gastric mucosa partly through increasing apoptosis and decreasing proliferative activity of the cells.

Previous studies have shown that apoptosis is the early effect of fumonisin on target organs (29, 30). FB1 may be considered as the first clear example of a non-genotoxic substance that can give rise to a tumor through different ways including apoptotic necrosis and atrophy (30). There are two possibilities; one is that the dead cells are not replaced and atrophy occurs, and the other is alteration in cell regeneration or proliferative activity of gastric basal cells. In previous study, we showed the changes of cell viability in a dose dependent manner of FB1. This toxin caused a decrease in the viability of gastric and intestinal cells (31, 32). In the present study, we showed that orally administration of FB1 for 16 weeks can induce apoptotic markers including increasing of BAX and fragmentation of DNA mouse gastric mucosa/, and can also alter balance between Bcl-2 and Bax proteins in gastric epithelial cells. Previous studies have suggested a correlation between gastric atrophy, apoptosis and alterations in the balance of Bcl-2 and Bax expression (33, 34). Similarly, an increased Bax expression and apoptosis but decreased Bcl-2 expression is shown in chronic atrophic gastritis (33, 34). Bcl-2 is an antiapoptotic gene family member; while Bax is a member of proapoptotic genes (35). Thus, these results suggest that an altered Bcl-2/Bax ratio may account for the atrophy-associated apoptosis in these mice models. On the other hand, FB1 has been identified as an inhibitor of ceramide enzyme, leading to significant alterations in sphingolipid metabolism, which is a key enzyme in sphingolipid metabolism, and various sphingolipids production involved in apoptosis (6, 36). Conceivably, chain of events linking FB1-induced ceramide synthase inhibition, disrupted sphingolipid metabolism and apoptosis induction can be theoretically drawn, raising the issue of apoptosis role in gastric atrophy.

On the other hand, previous studies have shown a strong relationship between the gastric atrophy and the onset of gastric and esophageus cancers (13-16). In addition, there is strong board of evidence proving that nitrosamines are esophageal cancer initiators, and mycotoxins such as FB1 can play a key role in the development of esophageal cancer (37). Acute gastric atrophy provides a proper environment for bacterial nitrosamines production (38). Nitrosamines from stomach origin can reach the mucus of esophagus through the gastric-esophageal blood vessel networks. Then, they can be converted to different active carcinogenic substances by P450 cytochrome isoforms existing in the mucus of esophagus (39). Therefore, endogenous nitrosamines produced by mycotoxins may etiologically play a role in esophageal and gastric cancer occurrence. However,
further studies are required to understand the possible roles of FB1 in the signaling pathways.

**Conclusion**

This study showed that the administration of FB1 for 16 consecutive weeks in mice can induce gastric mucosal atrophy partly through increasing apoptosis and decreasing proliferative activity of the cells.

**Conflict of interest**

The Author(s) declare(s) that they have no conflict of interest to disclose.

**Acknowledgment**

This study was supported by grant of Tehran University of Medical Sciences, Tehran, Iran.

**References**